TCM (524156)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a slight discount to book value: ₹45.83 vs ₹47.00, so P/B is below 1.
• Positive trailing ROE of 5.75% and ROCE of 6.32% show some existing capital efficiency despite the latest quarterly loss.
• Small market cap of ₹34 crore means the asset cushion per share is meaningful if a revival or restructuring is undertaken.
• Current price is well below the 52-week high of ₹81, reducing the froth that often surrounds small-cap chemical stocks.

Concerns

• Latest quarter is unprofitable: ₹6 crore sales and ₹1 crore net loss, making the 0.00 P/E uninterpretable.
• Sales growth is -7.93% and profit growth is -32.56%, showing real operating deterioration.
• Piotroski F-score of 3/9 signals weak financial health and possible balance-sheet stress.
• Zero dividend yield means minority shareholders receive no income while waiting for a recovery.

AI Analysis

Let me apply the Graham-Buffett lens to TCM. A ₹34 crore market cap commodity chemical company, trading at ₹45.83 against a book value of ₹47, looks like an asset play at first glance. But value investing is not buying cheap assets blindly; it is buying earning power at a discount. Here the earning power is missing. Sales have fallen 7.93%, profit growth is -32.56%, and the latest quarter shows a ₹1 crore net loss on ₹6 crore of sales. The P/E is meaningless because earnings are zero or negative. The Piotroski F-score of 3/9 is a serious red flag: it tells me the company's financial position is deteriorating, not stabilising. Return on equity of 5.75% and ROCE of 6.32% are far below what a commodity chemical maker needs to compensate for risk. There is no dividend, so I am not being paid to wait. The stock is down from the ₹81 high to the ₹45 level, but a falling price is not a margin of safety if the underlying asset value is also being eroded by losses. Graham would demand clean numbers, consistent earnings, and a clear catalyst. TCM seems to have none of these today. The book value of ₹47 is a useful cushion, but it will shrink if the company keeps losing money in a cyclical downturn. This may become a turnaround if management can arrest the sales decline and return to profitability, but I would need evidence in the next two or three quarters. For now, I classify this as an asset play, not a quality compounder. I will watch whether the balance sheet stays intact and whether the business can generate cash flow before considering an entry.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer